Prolonged survival in postoperative recurrent EGFR-L858R NSCLC: A 24-year case report

• Published in: Current problems in cancer. Case reports 2024-12, Vol.16, p.100329, Article 100329
• Main Authors: Go, Yoshihiro, Yoshizaki, Chinatsu, Yoshida, Yuki, Nohmi, Shiho, Kusakado, Rui, Saito, Yuichiro, Izumizaki, Kensuke, Ogawa, Takafumi, Suzuki, Takashi, Yamaguchi, Fumihiro
• Format: Article
• Language: English
• Subjects: EGFR L858R mutation; Epidermal growth factor receptor-tyrosine kinase inhibitor; Long-term survival; Non-small cell lung cancer; Postoperative recurrence
• ISSN: 2666-6219; 2666-6219
• DOI: 10.1016/j.cpccr.2024.100329

The use of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) is well-established for the treatment of advanced non-small cell lung cancer (NSCLC) patients with activating EGFR mutations. In this study, we report the long-term efficacy of EGFR-TKI therapy in a patient with postoperative recurrent NSCLC. A 58-year-old Japanese woman experienced recurrence after surgery, and an EGFR L858R mutation was identified. The patient continued gefitinib therapy for over 13 years, achieving a long-term survival of 21 years after postoperative recurrence, and 24 years after the initial diagnosis. This is the first report of a long-term response to EGFR-TKI therapy in an NSCLC patient with an L858R mutation. This case suggests the potential effectiveness of combining local therapy with EGFR-TKI treatment for metachronous oligometastatic disease.